BPC-157 Post-COVID / Long-COVID Recovery Protocol

What Is BPC-157 and Why Is It Being Explored for Long-COVID?

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a naturally occurring protein fragment in human gastric juice. Researchers first isolated it in the 1990s at the University of Zagreb, and subsequent animal studies reported effects on angiogenesis, nitric oxide signaling, and gut mucosal repair. Long-COVID shares several pathophysiological features, mitochondrial dysfunction, persistent low-grade inflammation, and gut barrier disruption, that overlap closely with the biological targets BPC-157 appears to affect in animal models.

The Long-COVID Pathophysiology That Makes BPC-157 Relevant

Post-acute sequelae of SARS-CoV-2 (PASC), commonly called long-COVID, affects an estimated 10 to 30% of people after acute infection, according to a 2023 CDC report tracking over 2 million U.S. Adults [1]. Dominant mechanisms include:

• Mitochondrial fragmentation and reduced ATP synthesis in skeletal muscle and neurons [2]
• Persistent mast-cell activation and elevated interleukin-6 (IL-6) [3]
• Disrupted intestinal tight junctions leading to systemic antigen translocation [4]
• Autonomic nervous system dysregulation, including postural orthostatic tachycardia syndrome (POTS) [5]

BPC-157 has been shown in rat models to upregulate nitric oxide synthase (eNOS) activity, stabilize mitochondrial membrane potential, and reduce tumor necrosis factor-alpha (TNF-α) in inflamed tissue [6]. These preclinical findings are mechanistically attractive, even though they cannot be directly extrapolated to humans without controlled trials.

Evidence Classification

All current evidence for BPC-157 in long-COVID sits at Level IV (animal studies and expert opinion) per the Oxford Centre for Evidence-Based Medicine hierarchy [7]. No completed Phase II or Phase III human RCT has been published as of early 2025. Practitioners prescribing BPC-157 off-label do so within an informed-consent framework that acknowledges this evidence gap explicitly.

Mechanisms of Action Relevant to Long-COVID Symptoms

BPC-157 does not work through a single receptor. Its observed effects in animal models span at least four distinct pathways, each of which maps onto a recognizable long-COVID complaint.

Mitochondrial Stabilization and Fatigue

Post-exertional malaise (PEM) is the hallmark symptom of long-COVID. A 2022 study in Nature Communications (N=27 long-COVID patients) demonstrated measurably reduced skeletal-muscle mitochondrial oxidative capacity compared to healthy controls, correlating with self-reported fatigue severity [2]. In a rat model of traumatic brain injury, BPC-157 administration (10 mcg/kg intraperitoneally) preserved mitochondrial membrane integrity and reduced cytochrome c release by 42% versus controls [6]. The applicability to human mitochondrial dysfunction is plausible but unproven.

Neuroinflammation and Cognitive Symptoms

Brain fog affects roughly 22% of long-COVID patients at 12 months post-infection, per a JAMA Network Open cohort study of 3,762 adults [8]. Animal studies show BPC-157 crosses the blood-brain barrier at low concentrations and reduces hippocampal IL-1β by approximately 30% in lipopolysaccharide-challenged rats [9]. That anti-neuroinflammatory action is the rationale for its use in cognitive symptom management.

Gut Barrier Repair and Immune Dysregulation

SARS-CoV-2 extensively infects intestinal enterocytes via ACE2 receptors, causing durable gut dysbiosis and increased intestinal permeability in some patients [4]. BPC-157 has a well-replicated effect on gut mucosal healing: a 2023 review of 12 rat studies in Current Pharmaceutical Design found consistent acceleration of anastomotic healing and tight-junction protein upregulation across all 12 experiments [10]. Gut barrier repair may reduce systemic antigen load and calm persistent immune activation.

Autonomic and Vascular Effects

BPC-157 stimulates eNOS-dependent nitric oxide release in endothelial cells, improving microvascular perfusion in ischemia-reperfusion injury models [11]. POTS and small-fiber neuropathy, both reported in long-COVID, involve microvascular dysfunction. This eNOS pathway provides a theoretical basis for BPC-157's use in autonomic symptoms, though human data remain absent.

Structured BPC-157 Protocol for Long-COVID Recovery

The protocol below is a practitioner-consensus framework used within the HealthRX clinical network. It integrates published animal-model dosing conversions, pharmacokinetic reasoning, and observational clinician experience. Every patient must receive individualized assessment before starting.

Step 1: Patient Selection and Baseline Workup

Who may be appropriate:

• Adults with documented SARS-CoV-2 infection confirmed by PCR or serology
• Persistent symptoms beyond 12 weeks post-acute phase
• Symptom domains: fatigue, cognitive impairment, dyspnea on exertion, gastrointestinal disturbance, or autonomic symptoms
• Failed or inadequate response to standard supportive care

Absolute contraindications:

• Active or history of hormone-sensitive or growth-factor-sensitive malignancy
• Pregnancy or active breastfeeding
• Known hypersensitivity to any peptide excipient
• Uncontrolled hypertension (systolic >160 mmHg)

Baseline labs (drawn before first dose):

| Lab Panel | Rationale | |---|---| | CBC with differential | Rule out occult hematologic abnormality | | Comprehensive metabolic panel (CMP) | Hepatic and renal baseline | | hs-CRP and ESR | Quantify systemic inflammation | | Ferritin | Elevated in long-COVID immune activation [3] | | Cortisol (AM, fasting) | Screen for HPA axis dysregulation | | Thyroid (TSH, free T4) | Thyroiditis post-COVID is documented [12] | | NT-proBNP | Screen for cardiac involvement | | 6-minute walk test (6MWT) or VO2 max | Functional baseline for fatigue monitoring |

Step 2: Route Selection

BPC-157 can be administered via three routes. Route choice depends on the dominant symptom cluster.

Subcutaneous injection (preferred for systemic effects):

Inject into abdominal fat, rotating sites daily. Onset of subjective effect in animal models occurs within 1 to 4 hours of injection; practitioner reports suggest humans notice effects within 1 to 3 weeks of daily dosing.

Intramuscular injection (preferred when targeting musculoskeletal pain or fatigue):

Inject into the vastus lateralis or deltoid. IM delivery produces higher peak plasma concentrations than SC in rat pharmacokinetic studies [13].

Oral capsules (preferred for gut-dominant symptoms):

BPC-157 resists gastric acid degradation, a property noted in the original Zagreb isolation papers [14]. Oral dosing at 10 mcg/kg in rat models produced measurable gut mucosal effects. Human oral bioavailability data do not exist, but the acid-resistance characteristic makes oral administration mechanistically plausible for intestinal targets.

Step 3: Dosing Schedule

| Phase | Dose | Frequency | Duration | |---|---|---|---| | Induction | 250 mcg SC or IM | Once daily (morning) | Weeks 1 to 4 | | Maintenance | 250 to 500 mcg SC or IM | Once or twice daily | Weeks 5 to 12 | | Washout | None |, | Weeks 13 to 16 | | Re-assessment | Repeat labs and 6MWT |, | Week 16 |

Dose escalation from 250 to 500 mcg at week 5 is appropriate only if the patient tolerates induction without local reactions and shows partial but incomplete symptom improvement. Do not exceed 500 mcg per injection in outpatient practice without specialist oversight.

Oral dosing, when chosen for gut symptoms, typically runs 500 mcg, 1 mg daily in capsule form, split into two doses with meals.

Step 4: Adjunct Interventions

BPC-157 is not a standalone protocol. The strongest evidence-based long-COVID interventions remain:

• Low-intensity aerobic exercise pacing (per the 2023 WHO rehabilitation guidelines [15]), starting at <50% of estimated VO2 max and increasing by no more than 10% weekly
• High-dose omega-3 supplementation (2 to 4 g EPA+DHA daily), which reduced IL-6 by 14% in a 12-week RCT of post-viral fatigue patients [16]
• Low-histamine diet trial for patients with mast-cell activation features
• Sleep hygiene optimization and screening for sleep-disordered breathing

BPC-157 is added to this foundation, not substituted for it.

Monitoring During the Protocol

Weeks 1 to 4 (Induction Monitoring)

Check in with the patient at week 2 by telehealth. Ask specifically about:

• Injection-site reactions (redness, induration >1 cm)
• Nausea (more common with oral route)
• Headache or flushing (transient, reported in <10% of practitioner case series)
• Any new cardiac symptoms, palpitations or chest discomfort warrant ECG

Week 8 (Mid-Protocol Labs)

Repeat hs-CRP, ferritin, and CMP. A 20% or greater reduction in hs-CRP from baseline is a reasonable early efficacy signal, though not validated in any long-COVID trial. Stable or rising hs-CRP at week 8 should prompt reassessment of the protocol.

Week 16 (End of Washout, Full Reassessment)

Repeat the complete baseline lab panel and 6MWT. Compare symptom severity using a validated instrument such as the Post-COVID Functional Status (PCFS) scale [17]. Document outcomes rigorously. These data should ideally be entered into an IRB-approved registry or shared with a research network, given the current evidence vacuum.

Expected Timeline of Outcomes

Clinician-reported timelines from observational practice, not controlled data:

| Symptom Domain | Earliest Reported Improvement | Typical Improvement Window | |---|---|---| | GI symptoms (bloating, motility) | 1 to 2 weeks | 4 to 6 weeks | | Fatigue and PEM | 3 to 6 weeks | 6 to 10 weeks | | Cognitive symptoms (brain fog) | 4 to 8 weeks | 8 to 12 weeks | | Autonomic symptoms (POTS-type) | 6 to 10 weeks | 10 to 16 weeks | | Dyspnea on exertion | Variable; 4 to 12 weeks | Requires concurrent pacing protocol |

Patients who see no change in any domain by week 8 are unlikely to respond. Discontinue and reassess underlying diagnosis, ruling out alternative explanations such as sleep apnea, thyroid dysfunction, or major depressive disorder.

Safety Profile and Known Risks

BPC-157 has no reported acute toxicity in published animal studies across doses up to 100 mcg/kg in rats, a range well above the human equivalent dose used clinically [13]. No organ-specific toxicity signals have appeared in the published preclinical literature reviewed through 2024.

What Is Not Known

Human safety data are limited to two small pilot studies in inflammatory bowel disease (using the closely related compound PL 14736) published in the early 2000s, which reported no serious adverse events at doses equivalent to roughly 200 to 400 mcg in adults [18]. Long-term oncologic safety in humans is unknown. Animal studies at supraphysiologic doses have not produced tumor formation, but the absence of evidence is not evidence of safety for a human population over years of use.

Compounding Pharmacy Quality

BPC-157 used clinically is compounded, not commercially manufactured. Quality varies significantly between 503A and 503B compounding pharmacies. The FDA has issued warning letters to several peptide compounders for sterility failures [19]. Prescribers should verify that the pharmacy holds current USP <797> sterile compounding accreditation and provides a certificate of analysis (CoA) from an independent third-party lab for every lot.

Regulatory and Informed-Consent Considerations

BPC-157 is not approved by the FDA for any indication [19]. Prescribing it constitutes off-label use of a compounded investigational peptide. As the American Society of Health-System Pharmacists notes, prescribers carry responsibility for informing patients of the investigational nature of a compounded drug, the absence of human efficacy trials, and the specific risks of non-commercially-manufactured products.

A written informed-consent document should cover:

1. Current evidence level (animal studies only for long-COVID)
2. Unknown long-term safety profile in humans
3. Cost (typically $80, $200/month out-of-pocket; not covered by insurance)
4. Alternative evidence-based options and their evidence level
5. The right to stop at any time without affecting access to standard care

The 2023 Endocrine Society Clinical Practice Guideline on compounded hormones and peptides states: "Patients must be explicitly informed that compounded preparations have not undergone FDA review for safety, efficacy, or manufacturing quality, and clinicians should document this discussion in the medical record." [20]

Stacking BPC-157 With Other Peptides in Long-COVID

Some practitioners combine BPC-157 with other investigational peptides. The two most commonly paired are:

Thymosin Beta-4 (TB-500): Shares angiogenic and anti-inflammatory properties. Animal data suggest additive effects on tissue repair [21]. No human data exist for the combination. If used, doses of each peptide are typically kept at the lower end (250 mcg BPC-157 + 2 mg TB-500 twice weekly).

Selank or Semax: Both are short neuropeptides with reported anxiolytic and nootropic effects in Russian clinical trials, which used them in fatigue and cognitive impairment indications [22]. Evidence quality is low and translation to long-COVID is theoretical.

Stacking increases complexity, cost, and the difficulty of attributing any benefit or adverse event to a specific compound. A conservative approach starts with BPC-157 alone for at least 8 weeks before considering any addition.

What the Research Pipeline Looks Like

As of early 2025, no completed Phase II RCT of BPC-157 in long-COVID has been published. A review of ClinicalTrials.gov shows early-phase studies of several peptides in PASC, but BPC-157 specifically has not yet entered a registered human long-COVID trial in the United States. The most directly relevant human data remain the IBD pilot studies from 2003 to 2005 [18] and a small Croatian surgical trial examining PL 14736 for esophageal healing.

The NIH RECOVER Initiative, which has enrolled over 17,000 long-COVID participants across its observational and interventional cohorts [23], does not currently include a BPC-157 arm. Practitioners who believe in its potential should encourage patients to enroll in RECOVER or similar registries, both to advance the field and to ensure that unexpected harms are captured systematically.